University of California, Los Angeles
ucla.eduTotal trials
1,150
Active
246
Phase 3
49
Total enrollment
9,288,813
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 87 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ropivacaine | — | — | — | — | 4 | ||
| Suzetrigine | — | — | — | — | — | 2 | |
| Tacrolimus | — | — | — | — | — | 3 | |
| Angiotensin II | — | — | — | — | 2 | ||
| Opioid Analgesics | — | — | — | — | — | 1 | |
| Scheduled Acetaminophen and Ibuprofen | — | — | — | — | — | 1 | |
| Metformin Extended Release (ER) Oral | — | — | — | — | — | 1 | |
| Envarsus XR | — | — | — | — | — | 1 | |
| Ibuprofen | — | — | — | — | — | 1 | |
| Norepinephrine | — | — | — | — | — | 1 | |
| Bupivacaine, lidocaine, ropivacaine | — | — | — | — | — | 1 | |
| Remimazolam | — | — | — | — | — | 1 | |
| Labetalol | — | — | — | — | — | 1 | |
| Nifedipine | — | — | — | — | — | 1 | |
| Multimodal Pain Regimen | — | — | — | — | — | 1 | |
| Acetaminophen | — | — | — | — | 3 | ||
| Oxycodone | — | — | — | — | 2 | ||
| Midazolam | — | — | — | — | 2 | ||
| Saline | — | — | — | 3 | |||
| Gastrografin | — | — | — | — | — | 1 | |
| BHV-4157 | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | 4 | |||
| Endotoxin | — | — | — | 7 | |||
| Sodium Lactate | — | — | — | — | — | 2 | |
| Insulin Detemir | — | — | — | — | — | 1 | |
| Insulin NPH | — | — | — | — | — | 1 | |
| Fimepinostat | — | — | — | — | — | 1 | |
| Cannabidiol (CBD) 800 mg | — | — | — | — | — | 1 | |
| Cytisinicline | — | — | — | — | — | 1 | |
| Benzathine penicillin 2.4 million units | — | — | — | — | — | 1 | |
| Donor Hematopoietic Stem and Progenitor Cell | — | — | — | — | — | 1 | |
| Brivaracetam | — | — | — | — | — | 1 | |
| A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme | — | — | — | — | — | 1 | |
| Testosterone Replacement Therapy | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| Famotidine | — | — | — | — | — | 1 | |
| Intravenous Alcohol | — | — | — | — | — | 1 | |
| Potassium Citrate | — | — | — | — | — | 1 | |
| Sodium Bicarbonate | — | — | — | — | — | 1 | |
| Buspirone | — | — | — | — | — | 1 |
47 more active programs hidden
Next readouts
- 2023-03-31
- 2023-12-31
- 2024-12-15
- 2025-06
- 2025-06-30
- 2025-07-31
- 2025-11-12
- 2025-12
- 2025-12
- 2025-12-04
Top conditions
- Depression56
- Anxiety30
- HIV26
- HIV Infections25
- Major Depressive Disorder23
- Schizophrenia22
- Obesity20
- Alcohol Use Disorder15
Frequently asked questions about University of California, Los Angeles
- How many clinical trials does University of California, Los Angeles have on ClinicalTrials.gov?
- University of California, Los Angeles is listed as the lead sponsor on 1,150 clinical trials in ClinicalTrials.gov, 246 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of California, Los Angeles's trials are in Phase 3?
- 49 of University of California, Los Angeles's trials are in Phase 3, spread across 87 active drug programs.
- What therapeutic areas does University of California, Los Angeles focus on?
- University of California, Los Angeles's most-studied conditions on ClinicalTrials.gov are Depression, Anxiety, HIV, HIV Infections, Major Depressive Disorder.
- When are University of California, Los Angeles's next clinical trial readouts?
- University of California, Los Angeles has 10 upcoming primary-completion readouts tracked here; the soonest is “Envarsus XR® in Adolescent Renal Transplant Recipients”, expected around 2023-03-31.